If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
2.30    0.00 (0.00%)
Bid:
2.10
Ask:
2.50
Spread: 0.40 (19.048%)
Market Cap: £10.05m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Director/PDMR Shareholding - Replacement

22 Jun 2021 13:25

RNS Number : 7366C
Renalytix AI PLC
22 June 2021
 

The following amendment(s) has been made to the ' Director/PDMR Dealing' announcement released on 22 June 2021 at 10:57 under RNS No 7062C.

 

The price of 113.5 pence per share was incorrect and has been amended to 1135 pence per share.

The Company was also informed of the sale 'yesterday'.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

Renalytix AI plc 

 

("Renalytix" or the "Company")

 

Director/PDMR Dealing

 

The Company was informed that yesterday, Christopher Mills, a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 1135 pence per share.

 

Following completion of the sale, Christopher Mills is interested in 9,180,501 Ordinary Shares representing 12.74% of the current issued share capital of the Company.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 

Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited as investment manager to North Atlantic Smaller Companies Investment Trust plc and Oryx

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Christopher Mills, non-exec director and Interim Chair of the issuer and director of NASCIT and Oryx International Growth Fund Ltd

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Renalytix AI plc

b)

 

LEI

 

 

213800NTOH3FK3WER551

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.0025 each

Identification code

GB00BYWL4Y04

 

 

b)

 

Nature of the transaction

 

 

Sale of shares

c)

Currency

GBP

d)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

£11.352941

17,000

 

 

 

 

 

e)

 

Aggregated information

- Aggregated volume

17,000

- Price

£192,999.99

f)

 

Date of the transaction

 

 

18 June 2021

g)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGZVZZFGMZM
Date   Source Headline
31st Oct 20224:36 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSRenalytix Reports Full Year Fiscal 2022 Results
26th Oct 20229:05 amRNSSecond Price Monitoring Extn
26th Oct 20229:00 amRNSPrice Monitoring Extension
25th Oct 20227:00 amRNSKidneyIntelX Medicare Update
24th Oct 20227:00 amRNSNotice of Results
17th Oct 20227:00 amRNSPresentations accepte at ASN Kiney Week
17th Oct 20227:00 amRNSPresentations accepted at ASN Kidney Week
20th Sep 20227:50 amRNSDirectorate Change
12th Sep 20227:00 amRNSIssue of shares
8th Sep 20227:00 amRNSRenalytix to Present at H.C. Wainwright Conference
17th Aug 202212:00 pmRNSBusiness update
8th Aug 20227:00 amRNSPublication of clinical utility study in The AJMC
30th Jun 20227:00 amRNSRenalytix Reports Financial Results for Q3 of FY22
23rd Jun 20227:00 amRNSRenalytix to Report Financial Results for Q3
10th Jun 20227:00 amRNSMount Sinai clinical utility data
8th Jun 20227:00 amRNSRenalytix to Present at Growth Stock Conference
6th Jun 20227:00 amRNSData Presentations at ADA 82nd Scientific Sessions
6th Jun 20227:00 amRNSKidneyIntelX data shows ability to assess risk
29th Apr 20224:46 pmRNSTotal Voting Rights
22nd Apr 20227:00 amRNSGrant of Share Options
8th Apr 20227:00 amRNSSuccessful completion of $30.0m financing package
8th Apr 20227:00 amRNSIssue of shares
31st Mar 20227:05 amRNS$30.0 million financing package
31st Mar 20227:00 amRNSHalf-year Report
30th Mar 20227:00 amRNSTimothy Scannell appointed to the Board
29th Mar 20227:00 amRNSEnrollment Milestone for KidneyIntelX
25th Mar 20227:00 amRNSNotice of Results
9th Mar 20227:00 amRNSRenalytix Launches myIntelX
24th Feb 20227:00 amRNSPresentation of new clinical data for KidneyIntelX
22nd Feb 20227:01 amRNSRENX to Present at Cowen 42nd Annual Conference
22nd Feb 20227:00 amRNSTimothy Scannell to be appointed to board
27th Jan 20223:19 pmRNSGrant of Share Options
27th Jan 20227:00 amRNSConference attendance
11th Jan 20221:06 pmRNSPositive Study Results Published for KidneyIntelX
10th Jan 20227:00 amRNSPartnership with Singing River for KidneyIntelX
7th Jan 20227:00 amRNSAppointment of Jean M. Casner as CHRO
5th Jan 20227:00 amRNSRENX to present at 40th JP Morgan Healthcare Conf.
4th Jan 20227:00 amRNSJoint program with American Diabetes Association
17th Dec 20213:38 pmRNSResult of AGM
17th Dec 202111:26 amRNSDirector/PDMR Shareholding
13th Dec 20217:00 amRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSDirector/PDMR Shareholding
8th Dec 20217:00 amRNSDirector/PDMR Shareholding
7th Dec 20217:00 amRNSRenalytix Reports Financial Results for Q1 of FY22
2nd Dec 20217:00 amRNSNotice of Q1 FY22 Results
19th Nov 20214:43 pmRNSPublication of Annual Report 2021 & Notice of AGM
10th Nov 20217:00 amRNSRenalytix Convenes Panel at VA Healthcare Summit
9th Nov 20217:00 amRNSPartnership with St. Joseph’s Health
1st Nov 202112:00 pmRNSIssue of shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.